Journal
CANCER SCIENCE
Volume 112, Issue 3, Pages 1225-1234Publisher
WILEY
DOI: 10.1111/cas.14786
Keywords
geldanamycin; HSP90; lung adenocarcinoma; proteasomal degradation; ROR1
Categories
Funding
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science
Ask authors/readers for more resources
The study identified geldanamycin as a potential inhibitor of ROR1 by destabilizing and degrading its protein expression through the ubiquitin/proteasome pathway, leading to a significant suppression of cell proliferation in lung adenocarcinoma cell lines. This suggests that HSP90 inhibition could be a promising therapeutic strategy in ROR1-positive lung adenocarcinoma.
We have previously identified receptor tyrosine kinase-like orphan receptor 1 (ROR1) as a direct transcriptional target of TTF-1/NKX2-1, a lineage-survival oncogene in lung adenocarcinoma. ROR1 sustains prosurvival signaling from multiple receptor tyrosine kinases including epidermal growth factor receptor, MET, and insulin-like growth factor 1 receptor in part by maintaining the caveolae structure as a scaffold protein of cavin-1 and caveolin-1. In this study, a high throughput screening of the natural product library containing 2560 compounds was undertaken using a cell-based FluoPPI assay detecting ROR1-cavin-1 interaction. As a result, geldanamycin (GA), a known inhibitor of heat shock protein 90 (HSP90), was identified as a potential inhibitor of ROR1. Geldanamycin, as well as two GA derivatives tested in the clinic, 17-allylamino-17-demethoxygeldanamycin (17-AAG) and 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), decreased ROR1 protein expression. We found that ROR1 physically interacted with HSP90 alpha, but not with other HSP90 paralogs, HSP90 beta or GRP94. Geldanamycin in turn destabilized and degraded ROR1 protein in a dose- and time-dependent manner through the ubiquitin/proteasome pathway, resulting in a significant suppression of cell proliferation in lung adenocarcinoma cell lines, for which the kinase domain of ROR1, but not its kinase activity or N-glycosylation, was required. Our findings indicate that HSP90 is required to sustain expression of ROR1 crucial for lung adenosarcoma survival, suggesting that inhibition of HSP90 could be a promising therapeutic strategy in ROR1-positive lung adenocarcinoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available